LUKE NORDQUIST, M.D., F.A.C.P.                  

 click to view this physician's blog

Click here for full CV

 "I take the fight against cancer personally. I lost my father to esophageal cancer.  I understand the disruption cancer causes in a family. Attempting to understand the disease, treatment options, and make life changing decisions can seem overwhelming. I strive to help each patient and family gain knowledge of their disease and treatment options so they are well prepared to make the best decisions possible. I have focused my time and efforts to develop an expertise in Urological Cancers. I remain active in patient care, research, and national committees for these tumors to ensure that I provide superior patient advice.”

Medical Director of Urology Cancer Center, CALGB GU core committee, and ASCO guidelines panel for advanced prostate cancer

EXPERTISE: Urological Cancers

  • Prostate Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Testicular Cancer

SPECIAL ACCOMPLISHMENTS:

  • Member of the American Society of Clinical Oncology Government Relations Committee.
  • 1 on 12 Oncologists chosen for ASCO Leadership Development Program 2010-2011.
  • President and Founder of Canceropinions.com an online oncology service for patients to receive expert second opinions
  • Founder & Chair of a local non-profit organization to raise support for the Lance Armstrong Foundation (Livestrong) and provide help to cancer patients and their families who are in need of assistance.
  • Member of the American Society of Clinical Oncology (ASCO) Expert Panel  for the Development of Guidelines for Advanced Prostate Cancer  2011-Present

PROFESSIONAL EDUCATION & TRAINING:

Oncology Fellowship: Memorial Sloan Kettering Cancer Center, New York & Weill Medical College of Cornell University, New York:

  • Clinical care and research focus involved in new treatments, including the development and role of vaccines, for advanced prostate cancer.

Residencies: Internal Medicine at the University of South Florida/H. Lee Moffitt Cancer Center

Medical School: M.D. Creighton University

Education: B.S. Pharmacy Creighton University

POSTDOCTORAL EDUCATION:

  • Memorial Sloan-Kettering Cancer Center Human Subjects Research Training Course
  • Memorial Sloan-Kettering Cancer Center Clinical Research Methodology Course
  • Rockefeller University Tri-Institutional Ethics in Research Course
  • Memorial Sloan-Kettering Cancer Center Biostatistics Course
  • New York Blood Bank Course

BOARD CERTIFICATIONS:

  • American Board of Internal Medicine: Internal Medicine
  • American Board of Internal Medicine: Medical Oncology
  • American College of Physicians: Fellow

CURRENT POSITIONS:

  • Active Provenge Vaccine site for advanced prostate cancer (Dendreon Oncall 1-877-336-3736) 
  • Member of the CALGB Genitourinary Core Committee: to develop national clinical trials for Genitourinary Cancers www.calgb.org
  • President-Elect of the Medical Staff, Alegent Health-Lakeside Hospital

PREVIOUS POSITIONS & APPOINTMENTS:

Associate Professor, Dept of Medicine, Hematology/Oncology, Creighton University

PROFESSIONAL ACTIVITIES, MEMBERSHIPS, & ACCOMPLISHMENTS:

 

  • Cadre Committee Member of Cancer and Leukemia Group B (CALGB) Genitourinary Tumors 2008-Present
  • Medical Executive Board Alegent Health Lakeside Hospital: Elected to a 6 year term consisting of:
        2008-2010: Secretary Treasurer
        2010-2012: Vice Chief of Staff
        2012-2014: Chief of Staff
  • Member of Alegent Health System Credentialing Board  2008-Present
  • Member of Alegent Health Lakeside Hospital Credentialing Board 2008-Present
  • Member of Alegent Health Lakeside Hospital Physician Excellence Committee  2008-Present
  • Member of Alegent Health Clinical Practice Committee 2010-Present
  • Member of Alegent Health Physician Collaboration Committee 2010-Present
  • Group Recipient of the 2009 ASCO Clinical Trials Participation Award. One of 8 sites in the U.S.
  • Group Recipient of the 2009 ASCO Community Oncology Research Grant. One of 2 sites in the U.S.

RESEARCH:

Cadre Committee Member of Cancer and Leukemia Group B (CALGB) Genitourinary Tumors Core Committee 2008-Present

Local Principal Investigator for Urologic Cancer Clinical Trials- Present

  1. A Randomized, Placebo-Controlled, Double – Blinded, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-line Chemotherapy in Men with Castrate Resistant Prostate Cancer
  2. An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy 
  3. A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
  4. A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing TAK-700 plus Prednisone with Placebo plus Prednisone in Patients with Chemotherapy naïve Metastatic Castration-resistant Prostate Cancer Protocol No. C21004
  5. A Phase 3, Randomized, Double-blind, Multicenter Trial Comparing TAK-700 plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer that has Progressed During or Following Docetaxel-based Therapy Protocol No. C21005 
  6. A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy
  7.  A Randomized Phase II study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
  8. Cougar 301 - Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
  9. Cougar 302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy

 

    Memorial Sloan Kettering Cancer Center, Division of Genitourinary Oncology

    Faculty Physicians: Scher, Howard M.D. 2002 – 2004

    1. Vaccination of Prostate Cancer Patients with Human and Mouse Prostate Specific Membrane Antigen DNA Vaccines: A phase I trial to assess safety and immune response: MSKK IRB #00-133
    2. Rapid Hormonal Cycling as Treatment for Patients with Prostate Cancer: The MEN’S Cycle: MSKCC IRB #01-085
    3. Rapid Hormonal Cycling as with Docetaxel as a Treatment for Patients with Hormonal Sensitive Prostate Cancer

    H. Lee Moffitt Cancer Center, Division of Thoracic Oncology

    Faculty Physician: Simon, George MD 2000 – 2001

    1. A Retrospective Study Comparing Survival Outcomes in Smokers vs. Never-Smokers with Adenocarcinoma of the Lung

    Creighton University, Department of Pharmacology and Toxicology
    Faculty: Stohs, S PhD, Roche, V PhD  1990 - 1991

    1. Glutathione Monoethyl Esters and Their Role in Preventing Lipid Peroxidation in the Liver
    2. D-glycosylamines with Derivatives of Glucose and Galactose to Form a Safe and Effective Antidote for Ricin Poisoning